Scrip
Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
18 August 2009
Malini Guha
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), met one of its co-primary endpoints, progression-free survival (PFS), but not the other, overall survival, in patients with KRAS wild-type metastatic colorectal cancer (mCRC) in the pivotal Phase III "181" trial testing it as...
Please Login to read the full article.
18 August 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- Mixed Phase III results for Erbitux in first-line colorectal cancer
- Vectibix fails pivotal trial in head and neck cancer
- New analysis seeks to find mutations that predict response to Amgen's Vectibix in colorectal cancer
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
